Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Sign Up
Cited by 3,256

The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.

Targeting RAS signalling pathways in cancer therapy

Downward, Julian·2003·Nature Reviews Cancer
DOI 10.1038/nrc969
Open this paper in CoChat — free account

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/nrc969

Cites

7 of 7 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 7 references

Research works printed but not linked: 80

  1. Barbacid, M. Ras genes. Annu. Rev. Biochem. 56, 779–827 (1987). · DOI · Paper page
  2. Bos, J. L. Ras oncogenes in human cancer: a review. Cancer Res. 49, 4682–4689 (1989).
  3. Shields, J. M., Pruitt, K., McFall, A., Shaub, A. & Der, C. J. Understanding Ras: 'it ain't over 'til it's over'. Trends Cell Biol. 10, 147–154 (2000). · DOI · Paper page
  4. Wittinghofer, A. Signal transduction via Ras. Biol. Chem. 379, 933–937 (1998). · DOI
  5. Lowy, D. R. & Willumsen, B. M. Function and regulation of ras. Annu. Rev. Biochem. 62, 851–891 (1993). · DOI · Paper page
  6. Johnson, L. et al. K-ras is an essential gene in the mouse with partial functional overlap with N-ras. Genes Dev. 11, 2468–2481 (1997). · DOI · Paper page
  7. Seabra, M. C. Membrane association and targeting of prenylated Ras-like GTPases. Cell Signal. 10, 167–172 (1998). · DOI · Paper page
  8. Cox, A. D. & Der, C. J. Farnesyltransferase inhibitors and cancer treatment: targeting simply Ras? Biochim. Biophys. Acta 1333, F51–F71 (1997).
  9. Hancock, J. F., Magee, A. I., Childs, J. E. & Marshall, C. J. All ras proteins are polyisoprenylated but only some are palmitoylated. Cell 57, 1167–1177 (1989). · DOI · Paper page
  10. Hancock, J. F., Paterson, H. & Marshall, C. J. A polybasic domain or palmitoylation is required in addition to the CAAX motif to localize p21ras to the plasma membrane. Cell 63, 133–139 (1990). References 10 and 11 describe the original characterization of the modification of RAS by farnesylation and, in the case of HRAS and NRAS, but not KRAS, palmitoylation. · DOI · Paper page
  11. Reuther, G. W. & Der, C. J. The Ras branch of small GTPases: Ras family members don't fall far from the tree. Curr. Opin. Cell Biol. 12, 157–165 (2000). · DOI · Paper page
  12. Takai, Y., Sasaki, T. & Matozaki, T. Small GTP-binding proteins. Physiol. Rev. 81, 153–208 (2001). · DOI · Paper page
  13. Cullen, P. J. & Lockyer, P. J. Integration of calcium and Ras signalling. Nature Rev. Mol. Cell Biol. 3, 339–348 (2002). · DOI · Paper page
  14. Daub, H., Weiss, F. U., Wallasch, C. & Ullrich, A. Role of transactivation of the EGF receptor in signalling by G-protein-coupled receptors. Nature 379, 557–560 (1996). · DOI · Paper page
  15. Ebinu, J. O. et al. RasGRP, a Ras guanyl nucleotide-releasing protein with calcium- and diacylglycerol-binding motifs. Science 280, 1082–1086 (1998). · DOI · Paper page
  16. Downward, J., Graves, J. D., Warne, P. H., Rayter, S. & Cantrell, D. A. Stimulation of p21ras upon T-cell activation. Nature 346, 719–723 (1990). · DOI · Paper page
  17. Donovan, S., Shannon, K. M. & Bollag, G. GTPase activating proteins: critical regulators of intracellular signaling. Biochim. Biophys. Acta 1602, 23–45 (2002).
  18. Leevers, S. J., Paterson, H. F. & Marshall, C. J. Requirement for Ras in Raf activation is overcome by targeting Raf to the plasma membrane. Nature 369, 411–414 (1994). · DOI · Paper page
  19. Marais, R., Light, Y., Paterson, H. F. & Marshall, C. J. Ras recruits Raf-1 to the plasma membrane for activation by tyrosine phosphorylation. EMBO J. 14, 3136–3145 (1995). · DOI · Paper page
  20. Yordy, J. S. & Muise-Helmericks, R. C. Signal transduction and the Ets family of transcription factors. Oncogene 19, 6503–6513 (2000). · DOI · Paper page
  21. Pruitt, K. & Der, C. J. Ras and Rho regulation of the cell cycle and oncogenesis. Cancer Lett. 171, 1–10 (2001). · DOI · Paper page
  22. Pacold, M. E. et al. Crystal structure and functional analysis of Ras binding to its effector phosphoinositide 3-kinaseγ. Cell 103, 931–943 (2000). This describes the three-dimensional structure of RAS in complex with one of its effectors, PI3K. The size of the interaction interface shows the difficulty that is likely to face the design of inhibitors of protein–protein interaction. · DOI · Paper page
  23. Khwaja, A., Rodriguez-Viciana, P., Wennstrom, S., Warne, P. H. & Downward, J. Matrix adhesion and Ras transformation both activate a phosphoinositide 3-OH kinase and protein kinase B/Akt cellular survival pathway. EMBO J. 16, 2783–2793 (1997). · DOI · Paper page
  24. Lambert, J. M. et al. Tiam1 mediates Ras activation of Rac by a PI(3)K-independent mechanism. Nature Cell Biol. 4, 621–625 (2002). · DOI · Paper page
  25. Malliri, A. et al. Mice deficient in the Rac activator Tiam1 are resistant to Ras-induced skin tumours. Nature 417, 867–871 (2002). · DOI · Paper page
  26. De Ruiter, N. D., Burgering, B. M. & Bos, J. L. Regulation of the Forkhead transcription factor AFX by Ral-dependent phosphorylation of threonines 447 and 451. Mol. Cell. Biol. 21, 8225–8235 (2001). · DOI
  27. Kelley, G. G., Reks, S. E., Ondrako, J. M. & Smrcka, A. V. Phospholipase Cε: a novel Ras effector. EMBO J. 20, 743–754 (2001). · DOI · Paper page
  28. Weiss, B., Bollag, G. & Shannon, K. Hyperactive Ras as a therapeutic target in neurofibromatosis type 1. Am. J. Med. Genet. 89, 14–22 (1999). · doi:10.1002/(sici)1096-8628(19990326)89:1<14::aid-ajmg5>3.0.co;2-4
  29. Mendelsohn, J. & Baselga, J. The EGF receptor family as targets for cancer therapy. Oncogene 19, 6550–6565 (2000). · DOI · Paper page
  30. Kuan, C. T., Wikstrand, C. J. & Bigner, D. D. EGF mutant receptor vIII as a molecular target in cancer therapy. Endocr. Relat. Cancer 8, 83–96 (2001). · DOI · Paper page
  31. Bellacosa, A. et al. Molecular alterations of the AKT2 oncogene in ovarian and breast carcinomas. Int. J. Cancer 64, 280–285 (1995). · DOI · Paper page
  32. Simpson, L. & Parsons, R. PTEN: life as a tumor suppressor. Exp. Cell Res. 264, 29–41 (2001). · DOI · Paper page
  33. Sebti, S. M. & Hamilton, A. D. Farnesyltransferase and geranylgeranyltransferase I inhibitors and cancer therapy: lessons from mechanism and bench-to-bedside translational studies. Oncogene 19, 6584–6593 (2000). · DOI · Paper page
  34. Cox, A. D. & Der, C. J. Farnesyltransferase inhibitors: promises and realities. Curr. Opin. Pharmacol. 2, 388–393 (2002). · DOI
  35. Kohl, N. E. et al. Inhibition of farnesyltransferase induces regression of mammary and salivary carcinomas in ras transgenic mice. Nature Med. 1, 792–797 (1995). The study that launched massive interest in farnesyl-transferase inhibitors as tumour therapeutic drugs aimed at RAS. Unfortunately, the activity turned out to be selective for HRAS, an isoform that is only very rarely activated in human tumours. · DOI · Paper page
  36. Lobell, R. B. et al. Evaluation of farnesyl:protein transferase and geranylgeranyl:protein transferase inhibitor combinations in preclinical models. Cancer Res. 61, 8758–8768 (2001).
  37. Prendergast, G. C. Actin' up: RhoB in cancer and apoptosis. Nature Rev. Cancer 1, 162–168 (2001). · DOI · Paper page
  38. Ohkanda, J., Knowles, D. B., Blaskovich, M. A., Sebti, S. M. & Hamilton, A. D. Inhibitors of protein farnesyltransferase as novel anticancer agents. Curr. Top. Med. Chem. 2, 303–323 (2002). · DOI
  39. Singh, S. B. & Lingham, R. B. Current progress on farnesyl protein transferase inhibitors. Curr. Opin. Drug. Discov. Devel. 5, 225–244 (2002).
  40. Cortes, J. E. et al. Efficacy of the farnesyl transferase inhibitor, ZARNESTRATM (R115777), in chronic myeloid leukemia and other other hematological malignancies. Blood 31, 31 Oct 31 2002 [epub ahead of print].
  41. Crooke, S. T. Potential roles of antisense technology in cancer chemotherapy. Oncogene 19, 6651–6659 (2000). · DOI
  42. Mukhopadhyay, T., Tainsky, M., Cavender, A. C. & Roth, J. A. Specific inhibition of K-ras expression and tumorigenicity of lung cancer cells by antisense RNA. Cancer Res. 51, 1744–1748 (1991).
  43. Chen, G., Oh, S., Monia, B. P. & Stacey, D. W. Antisense oligonucleotides demonstrate a dominant role of c-Ki-RAS proteins in regulating the proliferation of diploid human fibroblasts. J. Biol. Chem. 271, 28259–28265 (1996). · doi:10.1074/jbc.271.45.28259
  44. Monia, B. P., Johnston, J. F., Geiger, T., Muller, M. & Fabbro, D. Antitumor activity of a phosphorothioate antisense oligodeoxynucleotide targeted against C-raf kinase. Nature Med. 2, 668–675 (1996). · DOI · Paper page
  45. HŸser, M. et al. MEK kinase activity is not necessary for Raf-1 function. EMBO J. 20, 1940–1951 (2001). · DOI · Paper page
  46. Coudert, B. et al. Phase II trial with ISIS 5132 in patients with small-cell (SCLC) and non-small cell (NSCLC) lung cancer. A European Organization for Research and Treatment of Cancer (EORTC) Early Clinical Studies Group report. Eur. J. Cancer 37, 2194–2198 (2001). · DOI
  47. Sawyers, C. L. Rational therapeutic intervention in cancer: kinases as drug targets. Curr. Opin. Genet. Dev. 12, 111–115 (2002). · DOI
  48. Hoshino, R. et al. Constitutive activation of the 41-/43-kDa mitogen-activated protein kinase signaling pathway in human tumors. Oncogene 18, 813–822 (1999). · DOI · Paper page
  49. Dudley, D. T., Pang, L., Decker, S. J., Bridges, A. J. & Saltiel, A. R. A synthetic inhibitor of the mitogen-activated protein kinase cascade. Proc. Natl Acad. Sci. USA 92, 7686–7689 (1995). · DOI · Paper page
  50. Favata, M. F. et al. Identification of a novel inhibitor of mitogen-activated protein kinase kinase. J. Biol. Chem. 273, 18623–18632 (1998). · DOI · Paper page
  51. Sebolt-Leopold, J. S. Development of anticancer drugs targeting the MAP kinase pathway. Oncogene 19, 6594–6599 (2000). · DOI · Paper page
  52. Sebolt-Leopold, J. S. et al. Blockade of the MAP kinase pathway suppresses growth of colon tumors in vivo. Nature Med. 5, 810–816 (1999). · DOI · Paper page
  53. Lyons, J. F., Wilhelm, S., Hibner, B. & Bollag, G. Discovery of a novel Raf kinase inhibitor. Endocr. Relat. Cancer. 8, 219–225 (2001). · DOI · Paper page
  54. Normanno, N., Bianco, C., De Luca, A. & Salomon, D. S. The role of EGF-related peptides in tumor growth. Front. Biosci. 6, D685–D707 (2001). · DOI · Paper page
  55. Fabbro, D., Parkinson, D. & Matter, A. Protein tyrosine kinase inhibitors: new treatment modalities? Curr. Opin. Pharmacol. 2, 374–381 (2002). · DOI
  56. Wakeling, A. E. Epidermal growth factor receptor tyrosine kinase inhibitors. Curr. Opin. Pharmacol. 2, 382–387 (2002). · DOI
  57. de Bono, J. S. & Rowinsky, E. K. The ErbB receptor family: a therapeutic target for cancer. Trends Mol. Med. 8, S19–S26 (2002). · DOI · Paper page
  58. Herbst, R. S. ZD1839: targeting the epidermal growth factor receptor in cancer therapy. Expert Opin. Investig. Drugs 11, 837–849 (2002). · DOI
  59. Hidalgo, M. et al. Phase I and pharmacologic study of OSI-774, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignancies. J. Clin. Oncol. 19, 3267–3279 (2001). · DOI · Paper page
  60. Schulze, A., Lehmann, K., Jefferies, H. B., McMahon, M. & Downward, J. Analysis of the transcriptional program induced by Raf in epithelial cells. Genes Dev. 15, 981–994 (2001). · DOI · Paper page
  61. Herbst, R. S. & Shin, D. M. Monoclonal antibodies to target epidermal growth factor receptor-positive tumors: a new paradigm for cancer therapy. Cancer 94, 1593–1611 (2002). · DOI · Paper page
  62. Robert, F. et al. Phase I study of anti-epidermal growth factor receptor antibody cetuximab in combination with radiation therapy in patients with advanced head and neck cancer. J. Clin. Oncol. 19, 3234–3243 (2001). · DOI · Paper page
  63. Xie, Y., Li, K. & Hung, M. C. Tyrosine phosphorylation of Shc proteins and formation of Shc/Grb2 complex correlate to the transformation of NIH3T3 cells mediated by the point-mutation activated neu. Oncogene 10, 2409–2413 (1995).
  64. Keshamouni, V. G., Mattingly, R. R. & Reddy, K. B. Mechanism of 17-β-estradiol-induced Erk1/2 activation in breast cancer cells: A role for HER2 and PKC-δ. J. Biol. Chem. 277, 22558–22565 (2002). · DOI · Paper page
  65. Hunger, R. E. et al. Successful induction of immune responses against mutant ras in melanoma patients using intradermal injection of peptides and GM-CSF as adjuvant. Exp. Dermatol. 10, 161–167 (2001). · DOI
  66. Reuveni, H. et al. Toward a PKB inhibitor: modification of a selective PKA inhibitor by rational design. Biochemistry 41, 10304–10314 (2002). · doi:10.1021/bi0202530
  67. Bergo, M. O. et al. Absence of CAAX endoprotease Rce 1: effects on cell growth and transformation. Mol. Cell. Biol. 22, 171–181 (2002). · DOI
  68. Kloog, Y., Cox, A. D. & Sinensky, M. Concepts in Ras-directed therapy. Exp. Opin. Investig. Drugs 8, 2121–2140 (1999). · DOI
  69. Kimoto, M., Sakamoto, K., Shirouzu, M., Mirao, I. & Yokoyama, S. RNA aptamers that specifically bind to the Ras-binding domain of c-Raf-1. FEBS Lett. 441, 322–326 (1998). · DOI
  70. Kato-Stankiewicz, J. et al. Inhibitors of Ras/Raf-1 interaction identified by two-hybrid screening revert Ras-dependent transformation phenotypes in human cancer cells. Proc. Natl Acad. Sci. USA 99, 14398–14403 (2002). · DOI
  71. Ahmadian, M. R. et al. Guanosine triphopshatase stimulation of oncogenic Ras mutants. Proc. Natl Acad. Sci. USA 96, 7065–7070 (1999). · DOI
  72. Hidalgo, M. & Rowinsky, E. K. The rapamycin-sensitive signal transduction pathway as a target for cancer therapy. Oncogene 19, 6680–6686 (2000). · DOI · Paper page
  73. Neckers, L. Hsp90 inhibitors as novel cancer chemotherapeutic agents. Trends Mol. Med. 8, S55–S61 (2002). · DOI · Paper page
  74. Zucker, S., Cao, J. & Chen, W. T. Critical appraisal of the use of matrix metalloproteinase inhibitors in cancer treatment. Oncogene 19, 6642–6650 (2000). · DOI · Paper page
  75. Rosen, L. S. Angiogenesis inhibition in solid tumors. Cancer J. 7 (Suppl. 3), S120–S128 (2001).
  76. Kirn, D., Niculescu-Duvaz, I., Hallden, G. & Springer, C. J. The emerging fields of suicide gene therapy and virotherapy. Trends Mol. Med. 8, S68–S73 (2002). · DOI
  77. Biederer, C., Ries, S., Brandts, C. H. & McCormick, F. Replication-selective viruses for cancer therapy. J. Mol. Med. 80, 163–175 (2002). · DOI
  78. Raff, M. C. Social controls on cell survival and cell death. Nature 356, 397–400 (1992). · DOI · Paper page
  79. End, D. W. et al. Characterization of the antitumor effects of the selective farnesyl protein transferase inhibitor R115777 in vivo and in vitro. Cancer Res. 61, 131–137 (2001).
  80. Rose, W. C. et al. Preclinical antitumor activity of BMS-214662, a highly apoptotic and novel farnesyltransferase inhibitor. Cancer Res. 61, 7507–7517 (2001). References 86 and 87 describe preclinical data on two of the leading farnesyltransferase inhibitors. The significant effects that are seen in these model systems are probably not due to targeting RAS, and it remains unclear whether they can be replicated in the clinic.

Cited by

See all 3,256

Metadata

Authors
Downward, J.
Venue
Nature Reviews Cancer
Publisher
Springer Science and Business Media LLC
Published
2003-01
Volume
3
Issue
1
Pages
11-22
ISSN
  • 1474-175X (ISSN-L)
  • 1474-1768
DOI
10.1038/nrc969
OpenAlex
W2080719056
Cited by
3,256
References
7
FWCI
6.46
Type
journal article
Language
en
Open access
closed
Licence

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Targeting RAS signalling pathways in cancer therapy. https://app.cochat.ai/papers/10.1038/nrc969
The paper
Downward, J. (2003). Targeting RAS signalling pathways in cancer therapy. Nature Reviews Cancer. https://doi.org/10.1038/nrc969

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.